Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04372017 · ClinicalTrials.gov registry record · Phase 3
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
A Phase 3 study, sponsored by Sanford Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT04372017: Clinical Trial Phase 3 study, sponsored by Sanford Health.
NCT04372017 is a Phase 3 study that was terminated before completion, run by Sanford Health. The registered enrollment target is 1 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04372017, a Phase 3 study, was terminated before completion, sponsored by Sanford Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
Primary Outcome
Determine whether post-exposure prophylaxis with hydroxychloroquine can prevent COVID-19 in healthcare workers who have been exposed to a known case of COVID-19.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-05-14 |
| Est. Completion | 2021-06-04 |
| Phase | Phase 3 |
Why NCT04372017 stopped before completion
NCT04372017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Vitamin D is the first listed.
NCT04372017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04372017 about?
NCT04372017 is a clinical study titled "Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection". This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
What is the current status of trial NCT04372017?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2020-05-14. Estimated completion is 2021-06-04.
What interventions are being tested in trial NCT04372017?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04372017?
This trial is sponsored by Sanford Health, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04372017's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI